Navigation Links
Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
Date:2/11/2009

PALO ALTO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that it is implementing a reorganization to focus on its most advanced preclinical and clinical drug development programs. The reorganization will enable the company to continue the development of TELINTRA(R) and the two leading preclinical drug candidates: a prodrug cytotoxic, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404.

The restructuring will involve a workforce reduction of 44% primarily in early-stage discovery and support positions. Employees directly affected by the restructuring plan will receive severance payments, continuation of benefits and outplacement assistance. The company estimates incurring personnel-related restructuring charges of approximately $0.9 million in the first quarter of 2009.

"This reorganization will allow us to focus our resources on the clinical development of our lead compound, TELINTRA, currently in Phase 2 Studies for Myleodysplastic Syndrome and Chemotherapy Induced Neutropenia, as well as other potential indications. We also plan to advance our two leading preclinical drug candidates and continue to support our TRAP(R) technology collaborations," said Michael Wick, M.D., Ph.D., Chairman and Chief Executive Officer. "We are thankful for the significant contributions our employees have made."

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovar
'/>"/>

SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Telik Announces New TRAP Drug Discovery Agreement
2. Telik Announces Financial Results for 2008 Third Quarter
3. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
4. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
5. Telik Announces Receipt of Nasdaq Notice
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. ReceptorBio Announces Diabetes License Agreement With Telik
8. Telik Announces Financial Results For 2008 Second Quarter
9. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
10. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
11. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed drink ... term. They are the first functional focus beverage to ... an alternative to the temporary fix associated with energy ... July 29, 2014, with hopes to raise $50,000 over ... - http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks ...
(Date:7/23/2014)... , 23 de julio de 2014 ... la Compañía) ha anunciado hoy una asociación con ... (ABIA o el Instituto), para el propósito ... dispositivo de terapia de señal bioeléctrica (el E-QURE ... El Instituto, que tiene una importante experiencia en ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... July 23, 2014 With the ability to ... resolution for more than 15 minutes, Fastec Imaging has brought ... of high speed imaging. “Finally, a high speed camera that ... use in our everyday lives.” proclaims Matt Kearney, VP of ... always been to demystify and simplify the traditionally complicated workflow ...
Breaking Biology Technology:truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3
... , NES-ZIONA, Israel, July 27, PROLOR ... that it has entered into an evaluation and option agreement with ... the Weizmann Institute of Science . Under ... from Yeda a license to develop a number of peptide drug ...
... , , , ... medicine is just in its adolescence today and I see our ... applications and global markets," stated Edward Pulwer, upon accepting the position ... Sechrist has been in business for over 30 ...
... , CALGARY, July 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... with the support of its contract manufacturer, SAFC Pharma(R), ... an initial 100-litre production run of REOLYSIN under cGMP ... of a series to be completed over the next ...
Cached Biology Technology:PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 2PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug 3Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO 2Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2
(Date:7/23/2014)... especially the young, are highly sensitive to temperature and ... temperatures within a narrow range. Recently published research led ... School of Arts and Sciences, is the first to ... hive in process similar to how humans and other ... , "This study shows how workers effectively dissipate ...
(Date:7/23/2014)... fur seals, alongside decades of in-depth monitoring, has ... change on a population of top-predators. Published in ... that the seals have significantly altered in accordance ... with climate conditions. Despite a shift in the ... passing down through generations, leaving the population in ...
(Date:7/23/2014)... experiments using tissue samples cultured from cystic fibrosis patients, ... UNC Marsico Lung Institute have shown that a new ... another CF drug. , The finding, published today in ... a mutant CFTR protein becomes unstable and loses its ... the two drugs. The research offers several insights into ...
Breaking Biology News(10 mins):How honey bees stay cool 2Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... by Princeton University engineers could harness natural body ... pacemakers, mobile phones and other electronic devices. ... silicone rubber sheets, generates electricity when flexed and ... electrical energy. Shoes made of the material may ...
... by researchers with the U.S. Department of Energy,s Joint ... produce an advanced biofuel directly from biomass. Deploying the ... strain of Escherichia coli ( E. coli ) bacteria ... from fatty acids. "The fact that our microbes ...
... recent study at Oregon State University indicates that some past ... overestimated the number of live trees that burn up and ... a result. The research was done on the Metolius ... one-third or 100,000 acres of the area burned ...
Cached Biology News:Energy-harvesting rubber sheets could power pacemakers, mobile phones 2Microbes produce fuels directly from biomass 2Microbes produce fuels directly from biomass 3Effects of forest fire on carbon emissions, climate impacts often overestimated 2Effects of forest fire on carbon emissions, climate impacts often overestimated 3
...
... 4 deuterium atoms at the 3, 3', ... for use as an internal standard for ... LC-mass spectrometry. PGE1 is the theoretical cyclooxygenase ... is virtually undetectable in the plasma of ...
Direct ELISA Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: